| Dr Aisha Sabir, MD | |
|
281 N State St, Concord, NH 03301-3227 | |
| (603) 271-1844 | |
| Not Available |
| Full Name | Dr Aisha Sabir |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 24 Years |
| Location | 281 N State St, Concord, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1609970631 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084F0202X | Psychiatry & Neurology - Forensic Psychiatry | 12318 (New Hampshire) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Fairfax County, Virginia | 9739136847 | 85 |
News Archive
IBM on Monday announced the expansion of the company's Corporate Service Corps, which sends teams of professionals around the world "to work pro bono with local organizations and businesses on projects that intersect business, technology and society," Daily Independent/allAfrica.com reports.
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.
Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.
A research team led by scientists at the Chinese University of Hong Kong is releasing study results this week showing how a bacterium, Helicobacter pylori, that causes more than half of peptic ulcers worldwide and that has been implicated in stomach cancer has managed for eons to turn the acidic environment of the human gut into one in which it can thrive.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
› Verified 3 days ago
| Entity Name | Mental Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154356244 PECOS PAC ID: 6002701356 Enrollment ID: O20040217000340 |
News Archive
IBM on Monday announced the expansion of the company's Corporate Service Corps, which sends teams of professionals around the world "to work pro bono with local organizations and businesses on projects that intersect business, technology and society," Daily Independent/allAfrica.com reports.
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.
Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.
A research team led by scientists at the Chinese University of Hong Kong is releasing study results this week showing how a bacterium, Helicobacter pylori, that causes more than half of peptic ulcers worldwide and that has been implicated in stomach cancer has managed for eons to turn the acidic environment of the human gut into one in which it can thrive.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
› Verified 3 days ago
| Entity Name | Fairfax County, Virginia |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154356244 PECOS PAC ID: 9739136847 Enrollment ID: O20210319001688 |
News Archive
IBM on Monday announced the expansion of the company's Corporate Service Corps, which sends teams of professionals around the world "to work pro bono with local organizations and businesses on projects that intersect business, technology and society," Daily Independent/allAfrica.com reports.
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.
Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.
A research team led by scientists at the Chinese University of Hong Kong is releasing study results this week showing how a bacterium, Helicobacter pylori, that causes more than half of peptic ulcers worldwide and that has been implicated in stomach cancer has managed for eons to turn the acidic environment of the human gut into one in which it can thrive.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Aisha Sabir, MD 3 Waterford Way Unit 306, Manchester, NH 03102-8115 Ph: (603) 264-2127 | Dr Aisha Sabir, MD 281 N State St, Concord, NH 03301-3227 Ph: (603) 271-1844 |
News Archive
IBM on Monday announced the expansion of the company's Corporate Service Corps, which sends teams of professionals around the world "to work pro bono with local organizations and businesses on projects that intersect business, technology and society," Daily Independent/allAfrica.com reports.
CALGB 80405, a large, independent, phase III study, designed to assess the superiority in overall survival (OS) of cetuximab over Avastin (bevacizumab) when combined with either FOLFOX or FOLFIRI chemotherapy in people with previously untreated, KRAS wild-type advanced (metastatic) bowel cancer has failed to meet this primary endpoint.
Ardelyx, Inc., a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced financial results for the second quarter ended June 30, 2015.
A research team led by scientists at the Chinese University of Hong Kong is releasing study results this week showing how a bacterium, Helicobacter pylori, that causes more than half of peptic ulcers worldwide and that has been implicated in stomach cancer has managed for eons to turn the acidic environment of the human gut into one in which it can thrive.
Manipulation of cells by a new microfluidic device may help clinicians improve a promising cancer therapy that harnesses the body's own immune cells to fight such diseases as metastatic melanoma, non-Hodgkin's lymphoma, chronic lymphocytic leukemia and neuroblastoma.
› Verified 3 days ago
Samantha Gnanasegaram, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 36 Clinton St, Concord, NH 03301 Phone: 603-271-5485 | |
Dr. Alexandra I Kuftinec, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-227-7000 | |
Nicole S Ross, D.O. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 130 Pembroke Rd, Concord, NH 03301 Phone: 603-225-0123 | |
Dr. George William Luhrmann, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 36 Clinton St, Concord, NH 03301 Phone: 603-271-5300 Fax: 603-271-5395 | |
Olga Zhalkovska, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 250 Pleasant St, Concord, NH 03301 Phone: 603-227-7000 | |
R. Joffree Barrnett, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 36 Clinton St, Concord, NH 03301 Phone: 603-271-5907 Fax: 603-271-5962 | |
Dr. Mark Anthony Lombardo, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 246 Pleasant Street Memorial Building, West, Ground Flo, Concord, NH 03301 Phone: 603-224-6691 Fax: 603-228-7087 |